ALSO NOTED: AmerisourceBergen buys Bellco Health for $300M; UCB, Sanofi ship new allergy med Xycal;

> Pharma services company AmerisourceBergen completed its purchase of Bellco Health, a privately held drug distributor, for a cash price of about $190 million. Release

> UCB and Sanofi-Aventis announced that their new allergy drug Xyzal is now available in the U.S. Release

> Amylin, which got approval for its pen-injector form of the diabetes drug Symlin yesterday, wasn't so lucky with its request for key new uses of the drug. Release

> Abbott got an FDA waiver to sell a handheld blood analyzer to doctors' offices and other healthcare settings; previously, it could only be used in hospitals. Release

> The FDA gave Ranbaxy the go-ahead to make and sell an oral suspension of clarithromycin, the copycat form of Abbott Laboratories' Biaxin. Release

> Australia's CSL got the FDA nod for its flu vaccine and now plans to ship between mid-December and early February. Report

And Finally... Think research labs handling the world's most deadly germs are super careful? Sorry to burst your bubble, but these labs have lost shipments, and their workers have been repeatedly exposed to said deadly germs--and sometimes, the labs don't even report the mishaps. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.